Atomoxetine Off-Label Uses
Atomoxetine has limited evidence-based off-label indications, with the most supported being adjunctive therapy for ADHD when stimulants are partially effective, and treatment of ADHD with comorbid substance use disorders (particularly alcohol and cannabis use disorders). 1, 2
Primary Off-Label Indications
1. Adjunctive Therapy with Stimulants
- Use: When stimulant monotherapy provides incomplete symptom control or is limited by side effects 1
- Evidence level: Limited evidence supports efficacy and safety when combined with stimulants, though this remains off-label (guanfacine and clonidine are the only FDA-approved adjunctive agents) 1
- Dosing: Follow standard ADHD dosing protocols (see below)
2. ADHD with Comorbid Substance Use Disorders
Alcohol Use Disorder:
- Recommendation: Atomoxetine is recommended to reduce ADHD symptoms (weak recommendation) and alcohol craving (weak recommendation) 2
- Dosing: Standard adult dosing (40 mg initial, target 80 mg, maximum 100 mg daily) 3
Cannabis Use Disorder:
- Recommendation: Atomoxetine improves ADHD symptoms (weak recommendation) but does not reduce cannabis use 2
- Dosing: Standard adult dosing 3
Cocaine Use Disorder:
- Note: Methylphenidate is not recommended; atomoxetine may be considered as safer alternative given lack of abuse potential 2
Nicotine Use Disorder:
- Recommendation: Atomoxetine improves ADHD symptoms but does not reduce nicotine use 2
General SUD Population:
- Atomoxetine appears safe in patients with any SUD (strong recommendation) 2
- Improves ADHD symptoms but does not decrease substance use or improve treatment retention 2
3. Other Potential Off-Label Uses
The literature mentions atomoxetine is being examined for mood disorders, eating disorders, cognitive dysfunction, and addiction treatment, but these lack sufficient evidence for clinical recommendation 4
Standard Dosing Regimens (Applicable to Off-Label Use)
Children and Adolescents (≤70 kg):
Children and Adolescents (>70 kg) and Adults:
Titration Strategies
Slow Titration (Recommended to Minimize Adverse Events):
- Start with divided doses (morning and late afternoon/early evening) 5
- Increase gradually over several weeks 5
- Rationale: Slow titration with divided doses minimizes gastrointestinal symptoms, somnolence, and other adverse events in the first several weeks 6, 5
Once-Daily vs. Twice-Daily Dosing:
- Once-daily morning dosing is effective and may improve adherence 3
- However, once-daily dosing shows shorter time to onset of adverse events (particularly decreased appetite and nausea) 5
- Twice-daily dosing may reduce initial tolerability issues 5
When Switching from Stimulants:
- Cross-taper with methylphenidate is safe without undue cardiovascular concerns (though monitoring required) 6
- Stimulants can be discontinued abruptly without rebound effects 6
- Co-administration during switching period is acceptable 6
Trial Duration
Minimum trial period: 6-8 weeks, potentially longer 6
- Full therapeutic effects may take several weeks to manifest
- Adequate time needed to assess tolerability and efficacy after reaching target dose
- Some patients may require up to 8 weeks or more for full evaluation 6
Monitoring Parameters
Cardiovascular Monitoring (Critical):
- Baseline: Personal and family cardiac history, heart rate (HR), blood pressure (BP) 1
- Risk factors requiring ECG: History of sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome 1
- Ongoing: Monitor HR and BP throughout treatment 1, 4
- Expected changes: Increases in HR and BP (average 1-2 bpm for HR, 1-4 mmHg for systolic/diastolic BP) 1
- Contraindication: Severe cardiovascular disorders, pheochromocytoma 3, 4
Psychiatric Monitoring:
- Suicidal ideation: Close monitoring required, particularly in children/adolescents (FDA black box warning) 1, 3
- Screen for bipolar disorder before initiating treatment 3
- Monitor for: New psychotic/manic symptoms, aggressive behavior, hostility 3
Other Monitoring:
- Hepatic function: Discontinue if jaundice or laboratory evidence of liver injury develops 3
- Growth parameters: Height and weight in pediatric patients 3
- Urinary symptoms: Monitor for hesitancy, retention 3, 4
- Priapism: Educate patients to seek prompt medical attention 3
Special Populations Requiring Caution:
- Narrow angle glaucoma (contraindicated) 3, 4
- Epileptic seizures 4
- Tourette's syndrome 4
- Urinary outflow obstruction 4
- Pregnancy/lactation 4
Dose Adjustments
CYP2D6 Poor Metabolizers or Concomitant Strong CYP2D6 Inhibitors:
- Dose adjustment necessary 3
- Consider therapeutic drug monitoring (TDM) and CYP2D6 genotyping when possible 7, 8
Hepatic Impairment:
- Dose reduction required 3
Key Clinical Pearls
- No abuse potential: Unlike stimulants, atomoxetine has negligible risk of abuse or diversion 9
- Can be discontinued abruptly: No rebound effects or discontinuation syndrome 6
- Missed doses tolerable: Occasional missed doses do not cause problems 6
- Approximately 50% of methylphenidate non-responders will respond to atomoxetine 6
- Approximately 75% of methylphenidate responders will also respond to atomoxetine 6
Critical Safety Warnings
Do NOT use atomoxetine in patients with:
- Known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities 3
- Within 2 weeks of MAOI use 3
- Narrow angle glaucoma 3
- Pheochromocytoma or history thereof 3
Adult patients with clinically significant cardiac abnormalities should be carefully evaluated before considering atomoxetine 3